SolasCure partners with US Army for better wound care technology
Natalia Elliot | November 6, 2024 | News story | Research and Development | Dressings, hosiery & appliances, Solascare, US army, wound care, wound gel
SolasCure, a biotechnology company which is dedicated to working towards filling the current market gap in debridement – the removal of neurotic tissue to encourage healing – and healing solutions for chronic wounds has announced a partnership with the US Army’s Institute of Surgical Research (USAISR). The partnership has aims to improve the current solutions around treatment of wounds and wound care in combat situations.
An investigational product derived from medical maggots, the Aurase Wound Gel, produced by SolasCure, will be evaluated during the collaboration. The development of the gel is still underway, with goals including debridement and wound bed preparation. Plans to begin two non-clinical projects are also currently developing, and include the aims of reducing methicillin-resistant Staphylococcus aureus (MRSA) and pseudomonas aeruginosa both in vitro and in vivo. MRSA and pseudomonas aeruginosa infections are difficult to treat and damage tissue due to their production of enzymes and toxins, according to the press release.
Chief executive officer of SolasCure Lee Harle, commented: “It is an honour that the US military, one of the most prestigious and impressive institutions globally, has identified our technology and chosen to support its ongoing development. We look forward to the outcome of the projects to assess the suitability of Aurase Wound Gel for managing biofilm and bioburden in prolonged combat situations.”
The premier research laboratory for improving the care of combat casualties is currently the USAISR, and the partnership with wound-care specialist SolasCure could see development of Aurase Wound Gel impacting highly challenging combat conditions.
Natalia Elliot
6/11/24
Related Content
CMS commences formal review for Topical Oxygen Therapy coverage
11 November 2024 AOTI, INC. (AIM: AOTI), a medical technology group focussed on the durable …
FDA grants marketing approval for US Army’s malaria treatment
The FDA has granted marketing approval for the US Army Medical Research and Development Command’s …
Sanofi Zika vaccine deal causes controversy
In a further twist to Sanofi’s deal with the US Army to develop a vaccine …
